C57bl 6j sting1gt j

All animal experiments were developed under an Institutional Animal Care and Use Committee (IACUC) protocol (IS00009850) approved by the Integrity and Compliance board at the University of South Florida and Moffitt Cancer Center in accordance with the U.S. Public Health Service policy and National Research Council guidelines. Wild-type C57BL/6 (#000664) and STING^gt/gt (Goldenticket; C57BL/6J-Sting1^gt/J; #017537) mice were obtained from The Jackson Laboratory. All experiments were initiated using female mice between the ages of 8 and 10 weeks. Animals were housed in the Comparative Medicine Facilities at the Moffitt Cancer Center under temperature and humidity-controlled conditions with a 12-h light/dark cycle. At experimental endpoints, mice were humanely euthanized using CO₂ inhalation followed by cervical dislocation in accordance with American Veterinary Medical Association guidelines.

C57BL/6J (Stock #000664), C57BL/6J-Enpp1^asj/GrsrJ (Stock #012810), and C57BL/6J-Sting1^gt/J (Stock #017537) mice were purchased from the Jackson Laboratory. Enpp1^H362A were generated and characterized in house and bred with C57BL/6J-Sting1^gt/J mice to generate Sting1^−/−Enpp1^H362A mice. Male and female mice were included in every experiment, unless otherwise noted. Mice were maintained at Stanford University in compliance with the Stanford University Institutional Animal Care and Use Committee regulations. All procedures were approved by the Stanford University Administrative Panel on Laboratory Animal Care.

Eight-week-old male and female C57BL/6 N mice were obtained from Envigo. Tlr9^fl/fl (C57BL/6J-Tlr9^em1Ldm/J) mice with loxP sites flanking exon 1 of the Tlr9, Ifnar1^fl/fl (B6(Cg)-Ifnar1^tm1.1Ees/J) mice with loxP sites flanking exon 3 of the type-1 interferon α/β receptor gene, Rela^fl/fl (B6.129S1-Rela^tm1Ukl/J) mice with loxP sites flanking exon 1 of the Rela gene, and Sting1-knockout mice C57BL/6J-Sting1gt/J; Goldenticket (Tmem173gt) mice were obtained from Jackson Laboratory and bred in institutional facilities. All mice were eight weeks of age at the beginning of experiments, unless otherwise specified. All mice were group housed (12 h:12 h light:dark cycle with lights on at 07:00, temperature 20–22 °C, humidity 30–60%) with ad libitum access to food and water (mice were switched to single housing one week before experiments). All experimental groups were mixed sex, consisting of approximately equal numbers of males and females. All procedures were approved by Northwestern University’s Animal Care and Use Committee (protocols IS00002463 and IS00003359) and Albert Einstein’s Animal Care and Use Committee (protocols 00001289 and 00001268) in compliance with US National Institutes of Health standards, and at Aarhus University in compliance with the Danish National Animal Experiment Committee (protocol 2021-15-0201-00801).

The experiments on the mice were conducted according to the approval (KA2017-30) of the Animal Care Committee of Korea Advanced Institute of Science and Technology (KAIST). Specific pathogen-free C57BL/6 J, FVB/NJ, Balb/c, STING knockout (C57BL/6J-Sting1^gt/J), MMTV-PyMT transgenic [FVB/N-Tg(MMTV-PyVT)634Mul/J], LysM-Cre (B6.129P2-Lyz2^tm1(cre)Ifo/J), TNFR1 knockout (C57BL/6-Tnfrsf1a^tm1Imx/J), and B6.Cg-Tg(Tyr-cre/ERT2)13Bos Braf^tm1MmcmPten^tm1Hwu/BosJ (Tyr-Cre-ER^T2;Braf^CA;Pten^loxP) mice were purchased from Jackson Laboratory (USA). VE-cadherin-Cre-ER^T2 mice^{36 (link)} were provided by Prof. Yoshiyaki Kubota (Keio University, Japan), transferred, established and bred in SPF animal facilities at KAIST. STING1^{tm1a(EUCOMM)Hmgu} mice, which have conditional knockout potential with frt-flanked lacZ and neomycin resistance cassette followed by loxP-flanked exon 6, were purchased from EUMMCR. To generate STING^flox mice, STING^{tm1a(EUCOMM)Hmgu} mice were crossed with FLP1 recombinase expressing mice (B6;SJL-Tg(ACTFLPe)9205Dym/J), which were purchased from Jackson laboratory. All mice were fed with ad libitum access to standard diet (PMI lab diet) and water, and were anesthetized by i.p. injection of a combination of anaesthetics (80 mg/kg of ketamine and 12 mg/kg of xylazine) before all the procedures and being sacrificed.